Workflow
大健康国际(02211.HK)5月14日收盘上涨35.8%,成交566.94万港元

Company Overview - Dajiankang International Group Holdings Limited is a leading pharmaceutical retailer and distributor in Northeast China, operating the largest retail pharmacy chain and being the largest private pharmaceutical distributor in the region [2] - The company has 953 retail pharmacies in Northeast China and four in Hong Kong, all self-operated, with approximately 6,500 distribution clients [2] - Dajiankang International benefits from a high net profit margin due to its focus on high-margin branded products, unique direct supply model, centralized procurement platform, and low operating costs [2] Financial Performance - As of December 31, 2024, Dajiankang International reported total revenue of 441 million yuan, a year-on-year decrease of 25.4% [1] - The company recorded a net profit attributable to shareholders of -8.01 million yuan, an increase of 61.72% year-on-year [1] - The gross profit margin stood at 15.95%, with a debt-to-asset ratio of 43.83% [1] Market Position and Valuation - The average price-to-earnings (P/E) ratio for the pharmaceutical and biotechnology industry is 6.08 times, with a median of 5.56 times [1] - Dajiankang International has a P/E ratio of 4.36 times, ranking fourth in the industry [1] - Other companies in the industry have varying P/E ratios, with Jing Tian Pharmaceutical at 0.64 times, Kingsray Biotechnology at 0.99 times, Dongrui Pharmaceutical at 2.88 times, and others [1] Recent Developments - On May 13, 2025, the company plans to issue 304.4 million new shares, representing 27.54% of the enlarged share capital, at a subscription price of 0.08 HKD per share, reflecting a discount of 1.23% from the previous closing price [3]